Avoro Capital Advisors LLCAvoro Capital Advisors LLC

Institutional investor · Portfolio as of Q4 2020

Top Holdings44 positions

Checking export access…
Activity:
MRTXMRTXDelisted

MIRATI THERAPEUTICS INC

4.5M$996.1M17.2%——
8 qtrssince 2019-Q1
Increased
66

HORIZON THERAPEUTICS PUB L

9M$658.4M11.3%——
7 qtrssince 2019-Q2
Increased
73

UNITED THERAPEUTICS CORP DEL

2.9M$432.6M7.5%$151.790.00%
1 qtr
New
97

IOVANCE BIOTHERAPEUTICS INC

7.5M$348M6.0%$12.44+291.82%
8 qtrssince 2019-Q1
Decreased
0

ARENA PHARMACEUTICALS INC

4.2M$321.9M5.5%——
3 qtrssince 2020-Q2
Increased
79
ASNDASND
ADR

ASCENDIS PHARMA A/S

1.8M$300.2M5.2%$118.44+43.69%
8 qtrssince 2019-Q1
Unchanged
0

SAREPTA THERAPEUTICS INC

1.8M$298.4M5.1%$121.21+41.52%
8 qtrssince 2019-Q1
Increased
64
ARGXARGX
ADR

ARGENX SE

902,500$265.4M4.6%$132.04+122.73%
8 qtrssince 2019-Q1
Unchanged
0
FOLDFOLDDelisted

AMICUS THERAPEUTICS INC

9M$207.8M3.6%$12.98+76.70%
8 qtrssince 2019-Q1
Decreased
0

ACCELERON PHARMA INC

1.6M$198.3M3.4%——
4 qtrssince 2020-Q1
Increased
65
MRSNMRSNDelisted

MERSANA THERAPEUTICS INC

6.8M$180.9M3.1%$553.14+20.13%
3 qtrssince 2020-Q2
Unchanged
0

BIOMARIN PHARMACEUTICAL INC

1.7M$144.7M2.5%$84.82+2.52%
8 qtrssince 2019-Q1
Decreased
0

MADRIGAL PHARMACEUTICALS INC

1.2M$136.2M2.3%$117.71-5.56%
8 qtrssince 2019-Q1
Increased
69

KURA ONCOLOGY INC

4M$130.6M2.2%$28.23+20.40%
3 qtrssince 2020-Q2
Increased
76

PMV PHARMACEUTICALS INC

2.4M$130.5M2.2%$41.92+34.60%
2 qtrssince 2020-Q3
Increased
65

ACADIA PHARMACEUTICALS INC

2M$104.2M1.8%$53.690.00%
1 qtr
New
69
ADVMADVMDelisted

ADVERUM BIOTECHNOLOGIES INC

8M$86.7M1.5%———
Unchanged
0
TRILTRILDelisted

TRILLIUM THERAPEUTICS INC

5.8M$85.3M1.5%——
4 qtrssince 2020-Q1
Increased
51
CNSTCNSTDelisted

CONSTELLATION PHARMCETICLS I

3M$85M1.5%——
5 qtrssince 2019-Q4
Decreased
0
DCPHDCPHDelisted

DECIPHERA PHARMACEUTICALS IN

1.3M$74.2M1.3%——
5 qtrssince 2019-Q4
Decreased
0
$5.8B
AUM
44
Positions
Q4 2020
Filing
HI score · 2.5/5
Quarterly 13F Value Change
-17%Q3'19$2.4B+42%Q4'19$3.4B-13%Q1'20$3B+71%Q2'20$5.1B+39%Q3'20$7B-18%Q4'20$5.8B
Activity profile
$ moved · Q4'20
New17%Increased16%Decreased6%Exited62%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 3.5 quarters
<1Q18%1-4Q39%1-2Y43%2Y+0%

Avoro Capital Advisors LLC manages $5.8B across 44 positions as of Q4 2020. Top holdings: MRTX (17.2%), HZNP (11.3%), UTHR (7.5%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 2.5/5.0.

Q4 2020 Summary

Active quarter - 8 new positions, 11 exits, 12 increased. Top move: UTHR (NEW, conviction 97). Portfolio: $5.8B across 44 positions.

Top holdings by portfolio weight

Total AUM$6B
MRTX17.15%
HZNP11.34%
UTHR7.45%
IOVA5.99%
ARNA5.54%
ASND5.17%
SRPT5.14%
ARGX4.57%
FOLD3.58%
XLRN3.42%
Other3.12%

Portfolio allocation by GICS sector

Sectors2
Healthcare53.13%
Unknown46.87%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Healthcare, Unknown
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Solid(2.5 / 5.0)
Holdings P&L53
Conviction47
Concentration100
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
4Q
OCULOCULOCULAR THERAPEUTIX INC COM
Q3 2025 → Q2 2026+5.1M shares+$54.5M
3Q
UTHRUTHRUNITED THERAPEUTICS CORP DEL
Q4 2025 → Q2 2026+755,555 shares+$657.3M
2Q
ARWRARWRARROWHEAD PHARMACEUTICALS IN
Q1 2026 → Q2 2026+730,555 shares+$220.2M
Checking access…

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used